Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning ...
60 Degrees Pharmaceuticals reports 25,000 U.S. adults claim babesiosis-related medical costs annually, highlighting chronic fatigue as a potential symptom. Highlights significant discrepancy between ...
90-day trial will measure change in general fatigue in patients with chronic babesiosis following tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal ...
60 Degrees Pharmaceuticals has entered a clinical study agreement with the Icahn School of Medicine at Mount Sinai in the US, choosing it as the site to conduct an open-label Phase II trial of Arakoda ...
WASHINGTON, May 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious ...
Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient ...
In a new case study, researchers from North Carolina State University found Bartonella henselae, Babesia odocoilei and Babesia divergens-like MO-1 DNA in brain tissue samples from a young child with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results